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In many individuals, drug abuse is intimately linked with HIV-1 infection. In addition to
being associated with one-third of all HIV-1 infections in the United States, drug abuse
also plays a role in disease progression and severity in HIV-1-infected patients, including
adverse effects on the central nervous system (CNS). Specific systems within the brain
are known to be damaged in HIV-1-infected individuals and this damage is similar
to that observed in drug abuse. Even in the era of anti-retroviral therapy (ART), CNS
pathogenesis occurs with HIV-1 infection, with a broad range of cognitive impairment
observed, collectively referred to as HIV-1-associated neurocognitive disorders (HAND).
A number of HIV-1 proteins (Tat, gp120, Nef, Vpr) have been implicated in the etiology of
pathogenesis and disease as a result of the biologic activity of the extracellular form of
each of the proteins in a number of tissues, including the CNS, even in ART-suppressed
patients. In this review, we have made Tat the center of attention for a number of
reasons. First, it has been shown to be synthesized and secreted by HIV-1-infected
cells in the CNS, despite the most effective suppression therapies available to date.
Second, Tat has been shown to alter the functions of several host factors, disrupting
the molecular and biochemical balance of numerous pathways contributing to cellular
toxicity, dysfunction, and death. In addition, the advantages and disadvantages of ART
suppression with regard to controlling the genesis and progression of neurocognitive
impairment are currently under debate in the field and are yet to be fully determined.
In this review, we discuss the individual and concerted contributions of HIV-1 Tat, drug
abuse, and ART with respect to damage in the CNS, and how these factors contribute
to the development of HAND in HIV-1-infected patients.
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INTRODUCTION
The face of the HIV-1 pandemic has evolved from a progressively advancing life-threatening
disease in the absence of effective therapies to a manageable chronic clinical condition with the
development of effective combination antiretroviral therapy (ART). As a result of more effective
therapeutic control of HIV-1 disease for prolonged periods of time across the infected population,
many comorbid conditions have decreased in prevalence while some have increased. To this
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point, there has been a dramatic reduction in the prevalence
of the more severe forms of HIV-1-associated neurocognitive
disorders (HAND) including the most severe form, the
progressively debilitating HIV-1-associated dementia (HAD),
that was commonly observed at end-stage HIV-1 infection
in the absence of effective ART. However, there has been
an increase in the milder forms of disease encompassing a
spectrum of neurological symptoms, ranging from a clinically
asymptomatic neurocognitive impairment (ANI) to more
symptomatic presentations of cognitive impairment (Wadia
et al., 2001; Antinori et al., 2007). The mechanisms by which
HIV-1 infection promotes neuropathogenesis is based on viral
entry into the central nervous system (CNS) early during the
course of infection by breaching of the blood-brain barrier (BBB)
followed by a series of events that center around the neurotoxic
activity of a number of HIV-1 proteins including gp120, Tat, Vpr,
and likely others, along with alterations in CNS homeostasis that
involve the metabolic integrity of the blood-brain barrier and
metabolism of astrocytes, perivascularmacrophages, and resident
microglial cells. These are all events that lead to disruption of
neuronal physiology and increasing levels of death in this critical
cell population (Toborek et al., 2005; Rao et al., 2014) (Figure 1).
HIV-1 proteins (gp120, Tat, Vpr, and Nef) are released from
infected cells, either through secretion or after lysis of the cell,
throughout the course of infection and perpetuate an ongoing
burden in a number of tissues, including the CNS, resulting
in toxicity and damage, regardless of ART (Wang et al., 2006;
Strazza et al., 2011; Gresele et al., 2014). Of these, Tat (the
transactivator of transcription) is a viral protein, 101 amino
acids in length, known to be made and secreted early and
continuously by HIV-1-infected cells in the CNS throughout
infection and has been implicated in mediating and altering the
functions of several host factors, disrupting the molecular and
biochemical balance of numerous pathways, thus contributing
to cellular toxicity, dysfunction, and death (Ensoli et al., 1993;
Chang et al., 1997; Rappaport et al., 1999; Li et al., 2009). Tat
functions as the primary viral transcription factor, binding and
altering the function of a number of cellular players in the host
transcriptional machinery (Frankel and Young, 1998; Friedrich
et al., 2011; Ramakrishnan et al., 2012). The transactivator has
been shown to consist of six domains that have been linked
experimentally to a number of Tat-mediated consequences,
including both intracellular- and extracellular-triggered events
(Jeang et al., 1999; Debaisieux et al., 2012; Li et al., 2012).
Extracellular Tat has been shown to adversely impact a
number of cell types, exhibiting particularly negative effects
on cells of the CNS, including neurons, astrocytes, brain
microvascular endothelial cells (BMEC), and microglia, as well as
macrophages. Extracellular Tat protein is quickly and efficiently
taken up by uninfected neurons (Kolson et al., 1994) and
astrocytes (Ma and Nath, 1997) exerting direct and indirect
consequences on these and neighboring CNS cells. These
harmful outcomes include neuronal toxicity and dysfunction
via mitochondrial membrane hyperpolarization and aberrant
synaptic signaling (Chauhan et al., 2003; Norman et al., 2007),
altered dendritic arborization and morphology (Bruce-Keller
et al., 2003; Aprea et al., 2006), and deregulation of epigenetic
modulators (Saiyed et al., 2011). In addition, Tat exposure has
also been shown to mediate apoptosis (Acheampong et al., 2002;
Kim et al., 2003), alter molecular permeability (András et al.,
2003; Mahajan et al., 2008; Gandhi et al., 2010; Mishra and Singh,
2014), and enhance secretion of pro-inflammatory cytokines
(Acheampong et al., 2002; Woollard et al., 2014) from BMECs,
a primary component of the BBB.
These issues are further complicated by naturally occurring
comorbid diseases and conditions, the prevalence of which
appear to be accelerated or augmented in HIV-1-infected
patients, including increased permeability of the BBB and
an enhanced chronic pro-inflammatory state in the host, as
compared to the general population (Weiss et al., 2009; Scott
et al., 2011; Pirrone et al., 2013; Nasi et al., 2014). Moreover,
host genetics have been shown to play an irrefutable role in the
grand scheme of disease severity (if not incidence) and rate of
progression of neurocognitive deficits in all patients, regardless
of HIV-1 status, which is additionally confounded by lifestyle,
including but not limited to diet and exercise habits, medicinal
intake, therapy, and indulgence in recreational drugs (Nath et al.,
2002; Liu et al., 2012; Nasi et al., 2014; Smith et al., 2014).
Across four decades of increasingly effective therapies, the
HIV-1 protein Tat has been shown to play an important role
in viral replication and pathogenesis as both an intracellular
and extracellular protein. At present, in ART-naïve patients
experiencing varying degrees of immunological control, as well
as patients well-suppressed by ART, and patients experiencing
less than ideal responses to ART for numerous reasons, Tat has
continued to be a focus as a protein that may be produced
and released from cells in the absence or presence of infectious
virus production (Falkensammer et al., 2007; Mediouni et al.,
2012) with subsequent impact on immunologic and neurologic
function, to the detriment of the host. It has been suggested
that this may be one of the underlying mechanisms of HAND
(involving Tat production and release, leading to alterations in
inflammatory molecule production by interacting with cellular
gene promoters and cellular receptors to induce apoptosis and
cell death) (Rappaport et al., 1999; Bagashev and Sawaya, 2013).
With respect to drugs of abuse, it is widely known that drug
use is widespread in the HIV-1-infected community. It has also
been shown in a number of HIV-1-infected patient cohorts that
there are preferences with respect to the type of drugs used that
have been associated with the region of the United States or
part of the world wherein a patient resides. Consequently, these
preferences complicate our ability to understand how select drugs
interact with HIV-1 and its gene products. Furthermore, regional
differences in substance abuse profiles, and methodologies used
to define the types of substances used (e.g., self-reporting, medical
history, blood and/or urine analysis, as well as hair follicle
analysis) further complicates studies focused on understanding
the use of any single substance (Levine et al., 2014; Holtz
et al., 2015; Rosinska et al., 2015). These considerations are
further impacted by the fact that a majority of HIV-1-infected
individuals can test positive at any given clinical visit for three
or more substances that often include tobacco, alcohol, cocaine,
heroin, cannabis, and many others (Nishijima et al., 2013; Chang
et al., 2014; Huang et al., 2014; Ti et al., 2014). Given these
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FIGURE 1 | The blood-brain barrier (BBB) under normal and pathologic conditions. The BBB is a network of microvasculature composed primarily of
endothelial cells, astrocytes, and pericytes and functions as a selective, semi-permeable barrier, thus maintaining central nervous system (CNS) homeostasis and
(Continued)
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FIGURE 1 | Continued
regulating communication between the CNS and the periphery. The semi-permeable nature of the BBB, including cellular transmigration across the barrier, is regulated
through the expression of tight junction complexes, adherens junction complexes, and cell adhesion molecules. (A) Under normal homeostatic conditions, CNS
component cells of the BBB, as well as CNS immune regulators, are healthy and BBB integrity is properly maintained. During infection or other assault, activation of
select CNS cells results in a pro-inflammatory environment, yielding cellular, and tissue injury, including altered expression of cell adhesion molecules, adherens junction
proteins, and tight junction proteins, resulting in BBB compromise. (B) During HIV-1 infection, Tat protein mediates detrimental effects on specific cells, including CNS
component cells and CNS immune regulators, altering the activation status, and molecular profiles of several cell types, resulting in a pro-inflammatory environment,
and associated damage to the BBB. It is theorized that Tat is thus an important viral factor in the incidence and progression of HAND in HIV-1-infected patients.
considerations, understanding regional drug use demographics,
frequency of use, and blood levels are important factors to
consider in the data analysis phase of experimentation and in
formulating conclusions.
TAT AND DRUGS OF ABUSE IN THE CNS
Clinical reports, as well as experiments involving both in vitro
and in vivo investigations, have been instrumental in defining the
factors and pathways implicated in neurocognitive compromise
and their involvement in HAND. Drug use is a well-
known confounding factor that contributes to neurocognitive
impairment and the development of dementia. Within HIV-1-
infected populations, the widespread use of recreational drugs
(including opiates, amphetamines, cocaine, and ethanol) has
been shown to adversely impact the incidence and severity of
HAND (as well as other HIV-1-associated diseases), as compared
to non-users (Nath et al., 2002; Green et al., 2004; Sharma and
Ali, 2006; Theodore et al., 2007; Silverstein et al., 2011; Hauser
et al., 2012; Nair and Samikkannu, 2012; Rao et al., 2014). In
particular, the HIV-1 Tat protein has been identified, both in vitro
and in vivo, to perform in an additive or synergistic manner in
a number of experimental Tat—drug abuse co-exposure models
(Nath et al., 2002; Li et al., 2009).
Tat and Opiates
Of the four opioid receptors currently described in the literature
(i.e., delta, kappa, mu, and opioid-receptor-like1), the mu opioid
receptor is the most common target of currently available
opioids, both in the clinic and on the streets, and is expressed
in many tissues throughout the body including the CNS (Al-
Hasani and Bruchas, 2011; Feng et al., 2012). Morphine, which
is administered to patients as part of many pain management
regimens, is also a metabolic derivative of heroin, and binds the
mu opioid receptor with high affinity (Bell, 2014). The singular
and synergistic effects of HIV-1 Tat and opiates (specifically
morphine) on select cells of the CNS have been demonstrated
experimentally both in vitro and in vivo, providing biochemical
and cellular correlates for observed clinical manifestations
of HAND.
Utilization of an in vitro BBB model comprised of
primary human BMEC (hBMEC) and astrocytes in co-culture
demonstrated a decrease in barrier tightness coupled to a parallel
increase in immune cell transmigration as a result of either
Tat or morphine exposure, and BBB permeability was further
exacerbated by co-exposure to both agents simultaneously
(Mahajan et al., 2008). Exposure to either morphine or Tat also
resulted in diminished mRNA expression of the tight junction
proteins (TJP) occludin and zona occludens-1 (ZO-1), and a
concomitant increase in the cell adhesion molecule (CAM)
junctional adhesion molecule-2 (JAM-2) mRNA expression in
hBMEC, and these events were amplified by co-exposure to
both compounds (Mahajan et al., 2008). Mono-exposure of the
hCMEC/D3 BMEC line to Tat also resulted in the enhanced
nuclear translocation of ZO-1 within exposed cells (Zhong
et al., 2012), and Tat also downregulated mRNA and protein
expression of occludin of exposed primary hBMECs (Xu et al.,
2012). In addition, the proliferative capacity of primary murine
oligodendroglial progenitors was impeded (Hahn et al., 2012),
and activation of caspase-3 in primary murine oligodendrocytes
was augmented (Hauser et al., 2009), by exposure to either
morphine or Tat, and these effects were further potentiated
by co-exposure. Caspase-3 activation and apoptosis were
also upregulated in primary murine glial precursor cells by
mono-exposure to either Tat or morphine, in vitro (Buch et al.,
2007).
Primary murine astrocytes or microglia (Pu et al., 2003;
El-Hage et al., 2005, 2008; Bokhari et al., 2009), as well as
human U373 MAGI astrocytes and primary human monocytes
(Siddappa et al., 2006) exposed to Tat, and primary hBMEC
exposed to Tat or morphine (Mahajan et al., 2008) enhanced
secretion and mRNA transcript expression of a number of pro-
inflammatory cytokines (including IL-1B, IL-6, IL-8, MCP-1, and
TNFα), which was further augmented in both astrocytes and
BMEC by co-exposure of cells with both Tat and morphine.
Furthermore, exposure of primary murine microglia to either
morphine or Tat protein alone prompted nominal increases
in expression of CCR5, and differences in morphology and
activation status (Turchan-Cholewo et al., 2008; Bokhari et al.,
2009), as well as aberrant regulation and expression of opioid
receptors (Turchan-Cholewo et al., 2008; Bokhari et al., 2009),
which were all exacerbated by co-exposure (Turchan-Cholewo
et al., 2008; Bokhari et al., 2009). In addition, direct exposure to
either morphine or Tat enhanced migration of primary murine
microglia (Suzuki et al., 2011), while treatment with conditioned
media from Tat- or morphine-exposed astrocytes also enhanced
migration of the N9 murine microglia cell line (El-Hage et al.,
2006) in vitro. Notably, this escalation inmicroglial cell migration
was further increased by direct co-exposure to morphine and
Tat (Suzuki et al., 2011) or to media derived from co-exposed
astrocytes (El-Hage et al., 2006).
In vitro exposure to Tat increased intracellular sodium- and
calcium-ion concentrations in primary murine striatal neurons
(Fitting et al., 2014), as well as mitochondrial membrane
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depolarization in primary human and murine neurons, as well
as in the SHSY5Y human neuronal cell line (Malik et al., 2011;
Fitting et al., 2014), and these effects were dramatically amplified
by co-exposure with morphine, demonstrating increased Tat-
mediated neurotoxicity in the presence of opiates. Additionally,
an increase in apoptosis, as well as enhanced generation of
reactive oxygen species (ROS) by exposure to either Tat or
morphine alone, was further enhanced by co-exposure in both
primary human neurons and in SHSY5Y cells (Malik et al., 2011;
Suzuki et al., 2011). Interestingly, the neurotoxic consequences
of co-exposure were attenuated in primary murine neurons
in the presence of exogenous fractalkine treatment (Suzuki
et al., 2011), a neuroprotective chemokine shown to prevent
apoptosis of Tat-exposed primary rat neurons in vitro (Tong
et al., 2000) and constitutively produced in human brain tissue
(Wang et al., 2006), but downregulated by co-exposure to Tat
and morphine (Suzuki et al., 2011), suggesting the potential
for adjunctive fractalkine-enhancing therapy in HIV-1-infected
patients with HAND.
With respect to in vivo experimental results, utilization of
a doxycycline-inducible Tat-transgenic mouse model under
control of the human glial acidic fibrillary protein (GFAP)
promotor (allowing for brain-specific expression of Tat) was
shown to exhibit a higher percentage of activated microglia
and macrophages, as well as astrocytes, and this activation
was further potentiated by morphine treatment (through the
implantation of a slow-release subcutaneous pellet; Bruce-Keller
et al., 2008). Furthermore, neurons from Tat-transgenic mice
displayed an approximately 10-fold upregulation of caspase-3
expression, which was additionally boosted by treatment with
morphine (Bruce-Keller et al., 2008; Hauser et al., 2009). In
vivo induction of Tat in these transgenic mice also instigated
aberrant morphological changes in oligodendrocytes, including
diminished length and number of cellular processes, as well as
the presence of dendrite swelling and phenotypically abnormal
cell bodies (Hauser et al., 2009); curiously, morphine exposure
alleviated Tat-mediated effects on process lengths, however
all other aberrations were exacerbated. Both induction of
Tat in transgenics and subcutaneous injection of morphine
in Tat-negative mice resulted in decreased proliferative
capacity of brain cells, in general, and of undifferentiated and
oligodendroglial progenitors, in specific, which was additionally
reduced in morphine-treated Tat-transgenic mice (Hahn et al.,
2012). Behaviorally, subcutaneous injection of morphine
in non-transgenic mice and induction of Tat in transgenic
mice individually slowed reaction times and compromised
performance of exposed animals in nociception and balance
testing (Fitting et al., 2012), demonstrating independent effects of
these compounds that can combine to adversely impact general
neuro-functional outcomes in HAND.
Tat and Cocaine
Cocaine highjacks dopamine signaling pathways in vivo by
binding up the dopamine transporter in the synapse, thereby
causing increased localized concentration of dopamine and
heightened stimulation of receiving post-synaptic neurons, thus
exerting its effects which result in the well-known “high”
experienced by users (Nestler, 2005; Blaylock and Nader, 2012).
The consequences of in vitro exposure of CNS component cells to
mono- or co-exposure to Tat and cocaine has yielded interesting
observations with implications for CNS disease manifested in
cocaine-using patients with HAND.
Studies have indicated that exposure of primary rat neurons
to Tat alone resulted in a decrease in mitochondrial membrane
potential and cellular viability, as well as a concomitant increase
in the generation of intracellular ROS and enhanced protein
oxidation, all of which were significantly potentiated by co-
exposure to cocaine, in vitro (Aksenov et al., 2006). In addition,
mono-exposure of an in vitro BBB primary human BMEC-
astrocyte co-culture model to Tat or cocaine resulted in increased
BBB compromise and permeability, including an increase in
monocyte transmigration across the in vitro barrier, as well as
alterations in TJP (ZO-1) and CAM (JAM-2) expression (Gandhi
et al., 2010); observations which were further exacerbated by
exposure to both compounds in tandem.
In vivo, both acute (involving a 1-day interval) and chronic
(involving 7–14-day intervals) exposure to either cocaine by
intra-peritoneal (IP) injection, or intra-accumbal (IA) injection
of Tat, differentially deregulated the generation of extracellular
dopamine metabolites in the brains of exposed rats, and Tat-
mediated effects on metabolite levels were further exacerbated
by co-exposure to cocaine (Ferris et al., 2010). IP injection of
rats with cocaine alone enhanced neuronal excitability, however,
bathing of ex vivo pre-frontal cortex pyramidal neurons from
animals exposed in vivo to chronic (14 days of exposure) cocaine
with exogenous Tat further augmented neuronal excitability
(Napier et al., 2014), providing credence to an interactive role
of cocaine and Tat in observed neurocognitive impairment in
cocaine-using HIV-1-infected patients.
Behaviorally, cocaine mono-exposed animals (but not Tat
co-exposed animals) displayed a higher level of activity
than Tat-only or vehicle-controls, demonstrating diverging
behavioral consequences of cocaine use in the context of HIV-
1 infection (Ferris et al., 2010). Importantly, pre-exposure of
rats to IA-injected Tat amplified the effects of an acute 1-
day exposure to intravenous (IV) cocaine, but mitigated the
effects of a chronic 14-day exposure of cocaine to sensitization,
highlighting differences between acute vs. chronic cocaine use
during the course of in vivo Tat exposure (Harrod et al.,
2008). Furthermore, utilization of a brain-specific doxycycline-
inducible Tat-transgenic mouse model under control of the
murine GFAP promotor yielded several-fold increases in
cocaine-conditioned place preferences by Tat-induced mice after
subcutaneous injection of cocaine [cocaine-conditioned place
preference being a correlate for the rewarding effects of addictive
behavior, defined by the amount of time an animal spends in
the cocaine-associated chamber as compared to the pre-cocaine
baseline] (Paris et al., 2014). This observation provides evidence
that CNS expression of Tat is capable of intensifying cocaine-
additive behaviors in vivo.
Tat and Amphetamines
Amphetamines function similarly to cocaine in their ability to
interfere with dopamine signaling pathways, thus resulting in
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a build-up of dopamine in the synapse and over-stimulation
of post-synaptic neurons resulting in the characteristic “high”
experienced by users (Calipari and Ferris, 2013). Both in vitro and
in vivo experiments have been conducted in order to elucidate
the consequences of exposure to Tat and/or amphetamines on
relevant cells of the CNS, and how these may be involved in the
HAND outcomes observed in HIV-1-infected patients who use
amphetamines.
In vitro studies demonstrate susceptibility of primary rat
neurons to apoptosis by exposure to Tat (Theodore et al., 2006a),
and of SHSY5Y cells by treatment with methamphetamine (Qi
et al., 2011), with cellular viability further compromised by co-
exposure to both agents (Maragos et al., 2002; Theodore et al.,
2006a; Qi et al., 2011). Co-exposure of primary human neurons
to Tat andmethamphetamine also increased cell death, which was
accompanied by a decrease inmitochondrial membrane potential
(Maragos et al., 2002) and characterized by a concomitant
increase in the presence of autophagosomes (Qi et al., 2011).
In addition, exposure of primary human neuron-astrocyte co-
cultures to methamphetamine alone also enhanced secretion of
matrix metalloproteinase-1 (MMP-1), whereas exposure to Tat
upregulated secretion of bothMMP-1 andMMP-2 (Conant et al.,
2004), proteases capable of degrading select extracellular matrix
components, thus compromising BBB integrity. Transfection
of the U87MG human astrocyte cell line with Tat plasmid or
exposure of cells to methamphetamine inhibited beta-catenin
signaling, which was further diminished by co-exposure to both
compounds (Sharma et al., 2011). Furthermore, co-transfection
of CHME-5 human microglia cells with LTR- and Tat-containing
plasmids exposed to methamphetamine augmented HIV-1 LTR
transactivation by Tat, as well as NFκB nuclear translocation, in
a dose-dependent manner (Wires et al., 2012), underscoring a
potential cooperative relationship of amphetamines and Tat in
enhancement of viral replication in HIV-1-infected patients who
use amphetamines.
In vivo experiments have demonstrated upregulated
expression of a number of pro-inflammatory cytokines in
response to Tat and amphetamine exposure. Notably, both
TNFα secretion (Flora et al., 2003; Theodore et al., 2006a,b; Liu
et al., 2014) and mRNA transcript expression (Flora et al., 2003;
Theodore et al., 2006a,b; Liu et al., 2014) were upregulated in
models utilizing different routes of Tat administration [including
intra-striatal (IS) injection (Flora et al., 2003; Theodore et al.,
2006a,b; Liu et al., 2014), and intra-nigral (IN) micro-injection
(Flora et al., 2003; Theodore et al., 2006a,b; Liu et al., 2014) in
rats, and intra-hippocampal (IH) injection in mice (Flora et al.,
2003; Theodore et al., 2006a,b; Liu et al., 2014)], and TNFα levels
were further potentiated by IP injection with methamphetamine
in all models examined in these studies (Flora et al., 2003;
Theodore et al., 2006a,b; Liu et al., 2014). In addition, IL-1B
expression was also increased by IH injection of Tat in mice
(Flora et al., 2003; Theodore et al., 2006a,b; Liu et al., 2014) and
by IN injection of Tat in rats (Flora et al., 2003; Theodore et al.,
2006a,b; Liu et al., 2014), and further enhanced in both models by
IP injection with methamphetamine (Flora et al., 2003; Theodore
et al., 2006a,b; Liu et al., 2014). Moreover, IS administration of
Tat coupled with IP co-exposure of rats to methamphetamine
also augmented whole-tissue protein expression of IL-1α and
MCP-1 (Flora et al., 2003; Theodore et al., 2006a,b; Liu et al.,
2014). This deregulation of immune modulators was also
accompanied by a concomitant downregulation of serotonin,
dopamine, and dopamine metabolite levels in the brains of
co-exposed animals (Maragos et al., 2002; Cass et al., 2003;
Theodore et al., 2006a; Liu et al., 2014). Additionally, in vivo
exposure of mice to either IH Tat or IP methamphetamine
induced increases in oxidative stress, enhanced DNA-binding of
select redox-responsive transcription factors (e.g., AP-1, CREB,
and NFκB), and upregulated CAM (e.g., intercellular adhesion
molecule-1; ICAM-1) expression, which were all potentiated by
co-exposure (Flora et al., 2003). With respect to behavior, IN
Tat or IP methamphetamine alone impaired the performance
of rats in balance and locomotor tests, which were worsened
in co-injected animals (Liu et al., 2014), implying molecular
cooperation between Tat and amphetamines in the enhanced
cognitive deterioration observed in HIV-1-infected patients who
use amphetamines, thereby highlighting the need for improved
interventions and treatment options.
Tat and Ethanol
The pleiotropic effects of ethanol have long been appreciated
in the clinic and also reported in in vitro and animal model
studies. The multifaceted consequences of ethanol exposure have
also been extensively examine in the CNS, where ethanol has
been shown to have multiple (sometimes polarizing) effects on
a number of neurotransmitter receptors and their respective
pathways, including but not limited to aberrant modulation
of γ-aminobutyric acid type A (GABA-A) receptors and N-
methyl-D-aspartate (NMDA) receptors in the brain (Davies,
2003; Paul, 2006). The role of co-exposure to exogenous Tat
protein and ethanol on CNS cell populations cultured in vitro
and further examined in vivo infer adverse consequences for
alcohol-dependent HIV-1-infected patients.
In vitro experimentation involving exposure of primary
hBMEC to exogenously applied Tat showed elevated secretion
of TNFα from, and substantially increased apoptosis of, this
primary cell population (Acheampong et al., 2002) and these
effects were potentiated by co-exposure of hBMEC to ethanol
(Acheampong et al., 2002; Brailoiu et al., 2006). In addition, Tat
also enhanced intracellular calcium accumulation and apoptosis
in exposed primary rat cortical neurons, which was further
augmented in the presence of both compounds (Acheampong
et al., 2002; Brailoiu et al., 2006), demonstrating profound
cytotoxic effects of Tat on CNS cells that were accentuated in the
presence of ethanol.
Ex vivo mono- and co-exposure of primary rat hippocampal
explants to Tat and ethanol provided additional evidence of
Tat-mediated toxicity being augmented in the presence of
ethanol (Self et al., 2004), suggesting a tangible role for the
interaction of Tat and ethanol in the development of HAND
in HIV-1-infected patients; this was further corroborated by
behavioral reports of in vivo studies wherein rats chronically
exposed to ethanol (involving oral dosing three times a day
for four consecutive days) demonstrated significant withdrawal-
associated symptoms, which were potentiated by IH injection
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with Tat (Self et al., 2009). Moreover, co-exposed animals
exhibited sustained decreases in task performance in water maze
testing as compared to mono-exposed and control animals (Self
et al., 2009), indicating more severe cognitive decline in the
presence of Tat and exposure to ethanol. These behavioral results
in well characterized animal models were further supported by
clinical observations demonstrating more profound impairment
in HIV-1-infected patients with a history of alcohol abuse as
compared to HIV-1-positive non-alcohol-dependent or HIV-1-
negative participants, regardless of alcohol abuse history (Green
et al., 2004).
Biochemically, in vivo co-exposure of mice to IP injection
of ethanol or IH injection of Tat resulted in elevation of
ICAM-1 mRNA expression in brain tissue (Flora et al., 2005).
In addition, exposure to either ethanol or Tat individually
triggered increases in oxidative stress and proinflammatory
cytokines (IL-1B, MCP-1, and TNFα), that were augmented in
the hippocampus and corpus striatum of co-exposed mice (Flora
et al., 2005), demonstrating an amplification of Tat-mediated
immune deregulation in the brain by ethanol. Tat-transgenic
mice (in which Tat was constitutively expressed under control of
the simian virus 40 promoter) also exhibited significant defects
in innate immune function (as compared to non-transgenic
animals), and these were further exacerbated by either chronic
oral daily dosing with ethanol for 7 days (Prakash et al., 1998a,b)
or by acute dosing of one IP injection with ethanol (Prakash et al.,
1998a,b). Moreover, chronic exposure of Tat-transgenic mice
to ethanol and/or the drug azidothymidine (AZT) diminished
in vivo hematopoiesis, as compared to non-exposed animals
(Prakash et al., 2001), implying enhanced toxicity of cells of the
hematopoietic system co-exposed to Tat, ethanol, and/or AZT.
Tat and Cannabinoids
The endocannabinoid system is modulated by the expression of
two primary cannabinoid receptors, termed CB1 and CB2, which
demonstrate differential enriched expression in different tissues,
with CB1 receptors expressed primarily in the CNS and CB2
receptors expressed mostly on various immune cells (Pertwee,
2006; Mackie, 2008). In contrast to the predominantly negative
outcomes of most recreational drug use, there is evidence to
suggest a positive role for the use of cannabinoids (or simply
the activation of cannabinoid receptors), particularly within the
context of HIV-1 infection (Purohit et al., 2014).
Reports involving the use of in vitro experimental systems
have demonstrated the effects of co-exposure of cannabinoids
with HIV-1 Tat protein in cells relevant to the CNS. Exogenous
Tat exposure of the U-937 human monocyte cell line (which
express CB2, but not CB1) enhanced in vitro transmigration of
these cells across a porous polycarbonate transwell insert (Raborn
and Cabral, 2010; Raborn et al., 2014), as well as adhesion to
extracellular matrix (ECM) proteins (Raborn and Cabral, 2010;
Raborn et al., 2014), while pre-treatment of the monocytic cells
with cannabinoids blocked these Tat-mediated transmigration
and cellular adhesion effects (Raborn and Cabral, 2010; Raborn
et al., 2014). Morphologically, exposure to Tat induced U-937
cells to adopt a more adherent, activated macrophage-like
phenotype, whereas co-exposure with cannabinoids inhibited
this phenotypic metamorphosis, thus cells maintained a non-
activated monocyte-like phenotype (Raborn et al., 2014). At the
molecular level, Tat also enhanced expression of the CAM B1-
integrin on U-937 cells, an effect abrogated by co-treatment with
cannabinoids (Raborn et al., 2014).
Exposure of the C6 rat glial cell line (which express both
CB1 and CB2) with Tat yielded an increase of reactive nitrogen
species (RNS) and related enzymes, which was diminished by
co-exposure with a cannabinoid mimetic (Esposito et al., 2002).
In addition, Tat exposure increased GFAP mRNA and protein
expression in primary human Muller glia (which also express
both cannabinoid receptors), and this expression was reduced
by co-exposure with endocannabinoids, in vitro (Krishnan and
Chatterjee, 2014). Furthermore, a Tat-induced decrease in glial
viability was rescued by co-exposure with either a cannabinoid
mimetic (Esposito et al., 2002) or endocannabinoids (Krishnan
and Chatterjee, 2014).
Immunologically, Tat-mediated upregulation of a panel of
pro-inflammatory cytokines (e.g., IL-1B, IL-2, IL-8, IL-12,
IL-15, IFNγ, G-CSF, M-CSF, and TNFα) in primary human
Muller glia was dampened by co-exposure to endocannabinoids
(Krishnan and Chatterjee, 2014); remarkably, upregulation of
anti-inflammatory cytokine secretion (e.g., IL-10 and TGF-β)
by Tat was concomitantly enhanced in the presence of
endocannabinoids (Krishnan and Chatterjee, 2014), providing
evidence that cannabinoids skew cytokine production toward
an anti-inflammatory profile, and demonstrating a possible use
of cannabinoids in the treatment of select pro-inflammatory
conditions, including HIV-1-associated diseases such as HAND.
In support of in vitro studies, a clinical trial aimed at determining
the effects of cannabinoids in HIV-1-infected patients on ART
demonstrated that treatment with cannabinoids decreased serum
viral RNA levels, increased CD4+ and CD8+ T-cell counts, and
stimulated weight gain in HIV-1-positive patients on protease
inhibitors, implying an effective adjunctive therapeutic use of
cannabinoids in HIV-1-infected patients on ART (Abrams et al.,
2003).
ART AND DRUGS IN HAND
The development of more effective combinations of ART over
the past decade has been instrumental in the conversion of
HIV-1 infection from a rapidly progressing immunodeficiency
into a chronic, manageable condition with the development
and deployment of an ever-increasing number of antiretroviral
therapeutic agents in most industrialized countries. ART has
played a critical role in the reduction of HIV-1 viral loads,
boosting of CD4+ T-cell counts, and wide-ranging mitigation
of the most severe symptomology associated with many of
the comorbidities associated with HIV/AIDS in the earliest
era of the pandemic (Wang et al., 2006; Gresele et al., 2014).
These benefits were emphasized by early clinical reports of
declines in incidences and severity of neurocognitive deficits
and disturbances in HIV-1-infected patients using more effective
ART regimens, as compared to patients on mono-therapy or
no therapy (Ferrando et al., 1998; Price et al., 1999; Tozzi
et al., 1999; Cohen et al., 2001). Subsequent analyses, however,
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comparing clinical data before and after the implementation of
more effective combination therapeutic strategies have clearly
demonstrated that although the overall severity of HAND
exhibited in patients has declined with the introduction of
combination therapeutic approaches (with a skewing of HAND
symptoms to the less severe end of the spectrum) the incidence of
HAND has not decreased (Cysique et al., 2004; Robertson et al.,
2007; Tozzi et al., 2007; Heaton et al., 2010, 2011; Simioni et al.,
2010; Cysique and Brew, 2011).
Arguably, the benefits of viral load reduction and
improvement of the general health state of HIV-1-infected
patients comes at the cost of toxic side-effects characteristic
of current ART options (Meeker et al., 2014). Surprisingly,
some HIV-1-infected patients prescribed ART regimens with a
greater CNS penetration effectiveness (CPE) ranking exhibited
more impaired performance on neurocognitive assessments,
as compared to patients on regimens with a poorer CPE
ranking, despite improved suppression of viral replication
in the CNS compartment (Marra et al., 2009). In contrast,
patients in a different cohort on ART with high CPE ranking
demonstrated improved neurocognitive testing scores, but only
if their ART regimen consisted of more than three drugs overall
(Smurzynski et al., 2011). Interestingly, clinical data demonstrate
progressive and sustained improvements in performance on
neurocognitive assessments in HIV-1-infected patients who
voluntarily discontinued long-term ART (Robertson et al., 2010).
These results were observed even with continued HIV-1 viral
RNA and protein production (including Tat), persistent aberrant
immune activation, and enhanced amyloidosis in patients whose
HIV-1 infection was considered successfully managed on ART
(Falkensammer et al., 2007; Clifford et al., 2009; Yukl et al., 2009;
Giunta et al., 2011; Heaton et al., 2011; Mediouni et al., 2012;
Gresele et al., 2014; Smith et al., 2014), underscoring the demand
for more comprehensive, improved, and adjunctive therapies in
HIV-1-infected patients.
An important clinical consideration with regard to therapy
regimens, regardless of toxicity, is the potential for non-
adherence to ART, particularly in drug-abusing HIV-1-infected
patients, who demonstrate higher non-adherence as compared
to non-drug-abusing cohorts (Kamarulzaman and Altice,
2015; Kumar et al., 2015). This observation calls for the
development of additional intervention strategies in these
higher-risk populations, such as methadone maintenance
therapy in opioid abusers, which has demonstrated promise in
an increase in adherence compliance in these difficult-to-monitor
populations (Lappalainen et al., 2015). Further confounding
the HIV-1-infected patient treatment paradigm is the potential
for pharmacological interactions between ART and various
recreational drugs, as well as other prescription drugs or over-
the-counter drugs; interactions which are often unrecognized,
but commonly require dosing adjustments (Kumar et al., 2015;
Stolbach et al., 2015).
The limitations of current ART to eliminate HIV-1 from
patients despite long-term therapy or early therapeutic
intervention also highlights the importance of HIV-1 reservoirs
that remain unaffected by even the most rigorous therapeutic
regimens. The recently reported viral rebounds of the so-called
“Mississippi Baby” (Persaud et al., 2013; NIAID, 2014; Rainwater-
Lovett et al., 2015), the “Boston Patients” (Henrich et al., 2013),
and the VISCONTI cohort (Sáez-Cirión et al., 2013) demonstrate
an ineffectiveness of currently available ART to penetrate and
minimize or possibly eliminate HIV-1 reservoirs, which some
speculate to include a number of resident CNS cell populations,
including but not limited to perivascularmacrophages, microglia,
and astrocytes (Liner et al., 2010; Archin et al., 2014; Gray et al.,
2014; Fois and Brew, 2015; Joseph et al., 2015).
CONCLUSIONS
HIV-1 Tat mediates several detrimental consequences to multiple
CNS cell populations, both in vitro and in vivo, including
neurotoxicity, aberrant cellular activation, and endothelial
dysfunction (Figure 1). These pathologies have been anticipated
based on the spectrum of observed HAND manifested in HIV-
1-infected patients (Figure 2). Clinically, Tat mRNA and protein
has been consistently found in the brains of HIV-1 encephalitis
(HIVE) patients, where it has been linked to a number of
types of neurological impairment, including dementia (Hofman
et al., 1994; Hudson et al., 2000; Chang et al., 2011). Further
confounding these pathologies, genetic signatures identified
within and between HIV-1 subtypes demonstrate specific
phenotypic features associated with the incidence and severity of
HAND, including molecular and functional compromise of the
BBB (Spira et al., 2003; McArthur, 2004; Liner et al., 2007; Li
et al., 2012; Bertrand et al., 2013; Dahiya et al., 2013). In addition,
investigations by multiple groups have demonstrated that HIV-
1 Tat is indeed produced despite clinically successful ART in
well-controlled HIV-1-infected patients (Falkensammer et al.,
2007; Mediouni et al., 2012). Given these observations and the
fact that Tat-exposed animals exhibit many of the neurological
characteristics associated with HIV-1-infected patients, these
studies emphasize the need for improved therapies aimed at
the direct neutralization of Tat and/or the mitigation of Tat-
mediated effects in HIV-1-infected patients. These may include
small molecule inhibitors of Tat, which show promise in recent
in vitro and in vivo studies, demonstrating an ability to inhibit
Tat-dependent transcription (Mousseau et al., 2012), as well as
HIV-1 reactivation from latency (Mousseau et al., 2015), with the
ability to cross the BBB and prevent inflammation in the brains
of Tat-transgenic mice (Mediouni et al., 2015).
Drugs of abuse are their own confounding factor in
neurological impairment and decline, and the prevalence of
recreational drug use in the HIV-1-infected population continues
to present obstacles for greater clinical improvements in these
patients (Nath et al., 2002; Green et al., 2004; Sharma and
Ali, 2006; Theodore et al., 2007; Silverstein et al., 2011; Hauser
et al., 2012; Nair and Samikkannu, 2012; Smith et al., 2014;
Allain et al., 2015). Moreover, recreational drug and alcohol use
in HIV-1-infected patients, as well as the use of prescription
medications, over-the-counter drugs, and homeopathic regimens
for comorbid conditions, present the potential for dangerous
pharmacological interactions in this patient population (Stolbach
et al., 2015). Given these observations, there is a need for more
rigorous assessments of drug use in subsets of HIV-1-infected
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FIGURE 2 | Outcomes of HIV-1 Tat interactions with various recreational drugs and antiretroviral therapy (ART). (A) Tat or drug use alone are capable of
mediating significant damage to the CNS, however, these effects are often exacerbated in the context of comorbid illicit drug use in HIV-1-infected patients. In vitro
experiments have provided vital information on the multiple molecular-, cellular-, and tissue-altering effects of Tat in the absence and presence of drugs of abuse,
including opiates (op), cocaine (coc), amphetamines (amp), and ethanol (eth). One notable exception appears to be in the case of cannabinoids, which appear to
mitigate several of the negative consequences of Tat exposure, in vitro. (B) In vivo experiments further support in vitro data on the negative impact of drug use (e.g.,
ethanol) in the context of HIV-1 infection in patients on ART. Interestingly, a clinical report demonstrates a possible role for cannabinoids as an adjunctive therapy in
HIV-1-infected patients on ART.
patient populations by performing more robust drug screenings
and to question the current paradigm in order to truly appreciate
the impact that single- and poly-drug use really has on HIV-1
infection in general (Parikh et al., 2012, 2014). This would also
necessitate an understanding of the combined effects of alcohol
and tobacco in combination with any of the drugs previously
discussed, and will also increasingly need to include knowledge
and understanding of cannabinoids in their various formulations
as the growing legalization of this drug and its use in pain
management in the HIV-1-infected population is rising and
will likely become more prevalently used in time. In addition,
experimental and clinical Tat-mediated behavioral andmolecular
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effects are exacerbated in the presence of a number of drugs of
abuse, including opiates, cocaine, amphetamines, and ethanol
(Figure 2), underscoring the additional need for withdrawal
interventions and counseling in a large percentage of HIV-1-
infected patients. Nonetheless, the true impact of treatments used
for these drugs [including withdrawal effects both acutely (prior
to the next “hit”) and chronically (during long-term suppressive
therapy or by complete elimination of the drug(s))] has not
been well studied. Thus, withdrawal may have additional acute
and chronic effects on HIV-1 infection and associated disease
with one potential consequence being reactivation of virus from
reservoirs.
The development of ART has been critical in mitigating
symptomatic decline and improving the overall clinical condition
of those infected with HIV-1, as compared to the era
before effective combination therapeutic control was available.
However, the inability of current ART suppression to eliminate
HIV-1 reservoirs, including those in the CNS, underscores
the need for additional research into alternative strategies.
In this vein, recent in vitro findings utilizing gene-editing
technology to target and excise integrated HIV-1 proviral
genomes from latently infected cells exhibit exciting potential for
the development of the next generation of antiretroviral therapy
on the horizon (Hu et al., 2014). Indeed, the benefits of ART are
limited in the context of HAND progression in well-suppressed
patients, and several reports emphasize the need for improved
therapeutic alternatives in the current era of the HIV-1 pandemic
(Cysique et al., 2004; Robertson et al., 2007, 2010; Tozzi et al.,
2007; Marra et al., 2009; Heaton et al., 2010, 2011; Simioni
et al., 2010; Cysique and Brew, 2011; Smurzynski et al., 2011).
Thus, the advantages and disadvantages of ART with regard to
neurocognitive impairment are currently under debate in the
field and are yet to be fully determined.
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